Scilex Holding Co SCLX
Scilex Holding Co (Nasdaq: SCLX) is a pain/anesthesia drug developer. Its lead program, ZTlido (lidocaine topical system) 1.8%, is in Phase 3 for neuropathic pain associated with postherpetic neuralgia.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ZTlido (lidocaine topical system) 1.8% | postherpetic neuralgia | small molecule | Approved |
| ELYXYB (celecoxib oral solution) | acute treatment of migraine in adults | small molecule | Approved |
| GLOPERBA (colchicine oral solution) | prophylaxis of gout flares in adults | small molecule | Approved |
| SP-102 (SEMDEXA, dexamethasone sodium phosphate viscous gel) | lumbosacral radicular pain (sciatica); second Phase 3 (CLEAR-2) started Sept 2025 | small molecule | Phase 3 |
| SP-103 (lidocaine topical system 5.4%) | chronic neck pain associated with muscle spasms / acute low back pain | small molecule | Phase 2 |
| SP-104 (low-dose naltrexone delayed-release) | fibromyalgia | small molecule | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 pain/anesthesia companies
- Mesoblast Ltd MESO
- Not specified in extract Not specified in extract
- Ensysce Biosciences, Inc. ENSC
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.